KZIA Key Statistics, Chart & Performance
The current stock price of KZIA is 5 USD. In the past month the price decreased by -62.26%. In the past year, price decreased by -44.44%.
KZIA Latest News, Press Relases and Analysis
KZIA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.27 | 405.28B | ||
| AMGN | AMGEN INC | 14.98 | 176.43B | ||
| GILD | GILEAD SCIENCES INC | 14.85 | 150.87B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.04 | 114.71B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.25 | 81.59B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 784.65 | 52.87B | ||
| INSM | INSMED INC | N/A | 37.77B | ||
| NTRA | NATERA INC | N/A | 31.58B | ||
| BIIB | BIOGEN INC | 10.62 | 26.09B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.82 | 21.39B | ||
| INCY | INCYTE CORP | 15.8 | 19.91B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.31B |
Related stock screener links
About KZIA
Company Profile
Kazia Therapeutics Ltd. is an oncology-focused biotechnology company, which engages in the business of pharmaceutical drug development. The company is headquartered in Sydney, New South Wales. The firm operates in the pharmaceutical research and development business. The Company’s lead program is paxalisib, an investigational brain-penetrant inhibitor of the PI3K / Akt / mTOR pathway, which is being developed to treat multiple forms of brain cancer. The company is also developing EVT801, a small-molecule inhibitor of VEGFR3, which is critical to the development of new blood vessels and lymphatic vessels in a growing tumor, as well as to the metastasis of tumors to distant sites in the body. The company designed paxalisib to inhibit PI3K, a critical control mechanism in growth and cell division, which is activated in many forms of cancer. The Company’s drug candidates are designed to treat diseases, such as brain cancer, renal cancer, and liver cancer.
Company Info
KAZIA THERAPEUTICS-SPON ADR
Three International Towers Level 24,, 300 Barangaroo Avenue
Sydney NEW SOUTH WALES 2000 AU
CEO: James Garner
Employees: 13
Phone: 1161298780088
KAZIA THERAPEUTICS-SPON ADR / KZIA FAQ
What does KZIA do?
Kazia Therapeutics Ltd. is an oncology-focused biotechnology company, which engages in the business of pharmaceutical drug development. The company is headquartered in Sydney, New South Wales. The firm operates in the pharmaceutical research and development business. The Company’s lead program is paxalisib, an investigational brain-penetrant inhibitor of the PI3K / Akt / mTOR pathway, which is being developed to treat multiple forms of brain cancer. The company is also developing EVT801, a small-molecule inhibitor of VEGFR3, which is critical to the development of new blood vessels and lymphatic vessels in a growing tumor, as well as to the metastasis of tumors to distant sites in the body. The company designed paxalisib to inhibit PI3K, a critical control mechanism in growth and cell division, which is activated in many forms of cancer. The Company’s drug candidates are designed to treat diseases, such as brain cancer, renal cancer, and liver cancer.
What is the current price of KZIA stock?
The current stock price of KZIA is 5 USD. The price decreased by -27.43% in the last trading session.
What is the dividend status of KAZIA THERAPEUTICS-SPON ADR?
KZIA does not pay a dividend.
What is the ChartMill technical and fundamental rating of KZIA stock?
KZIA has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
What is the employee count for KZIA stock?
KAZIA THERAPEUTICS-SPON ADR (KZIA) currently has 13 employees.
What is the market capitalization of KZIA stock?
KAZIA THERAPEUTICS-SPON ADR (KZIA) has a market capitalization of 8.35M USD. This makes KZIA a Nano Cap stock.
What is the ownership structure of KAZIA THERAPEUTICS-SPON ADR (KZIA)?
You can find the ownership structure of KAZIA THERAPEUTICS-SPON ADR (KZIA) on the Ownership tab.
KZIA Technical Analysis
KZIA Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to KZIA. KZIA may be in some trouble as it scores bad on both profitability and health.
KZIA Financial Highlights
Over the last trailing twelve months KZIA reported a non-GAAP Earnings per Share(EPS) of -14.03. The EPS increased by 93.01% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -158.6% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
KZIA Forecast & Estimates
8 analysts have analysed KZIA and the average price target is 19.38 USD. This implies a price increase of 287.6% is expected in the next year compared to the current price of 5.
For the next year, analysts expect an EPS growth of 64.71% and a revenue growth -25.37% for KZIA